Educational content on VJHemOnc is intended for healthcare professionals only. By visiting this website and accessing this information you confirm that you are a healthcare professional.

Share this video  

EHA 2018 | A new set of treatment options for low-risk MDS

Treatments for low-risk myelodysplastic syndromes (MDS) cannot cure the disease, but rather aim to improve quality of life, reduce complications and increase overall survival by reducing cytopenia. In this video, recorded at the 23rd Congress of the European Hematology Association (EHA) 2018, held in Stockholm, Sweden, Esther Oliva, MD, Esther Oliva, MD, Chair of the European Haematology Association Scientific Working Group (EHA-SWG), from the Grande Ospedale Metropolitano Bianchi Melacrino Morelli, Reggio Calabria, Italy, discusses new treatment options for low-risk MDS. Therapies include: epoetin alfa for stimulating erythropoiesis; lenalidomide for modulating the immune system; luspatercept for correcting ring sideroblasts; and eltrombopag for treating severe thrombocytopenia.